Skip To Content
Click for DHHS Home Page
Click for the SAMHSA Home Page
 Click for the OAS Drug Abuse Statistics Home Page
Click for What's New
Click for Recent Reports and HighlightsClick for Information by Topic Click for OAS Data Systems and more Pubs Click for Data on Specific Drugs of Use Click for Short Reports and Facts Click for Frequently Asked Questions Click for Publications Click to send OAS Comments, Questions and Requests Click for OAS Home Page Click for Substance Abuse and Mental Health Services Administration Home Page Click to Search Our Site


The DAWN Report: ED Visits Involving the Muscle Relaxant Carisoprodol

Highlights:

The number of carisoprodol-related ED visits involving misuse or abuse doubled from 15,830 visits in 2004 to 31,763 visits in 2009. The number of carisoprodolrelated ED visits involving misuse or abuse by patients aged 50 or older tripled between 2004 and 2009 (from 2,070 to 7,115 visits). The majority of ED visits involving carisoprodol also involved other pharmaceuticals (77 percent); the most common combinations involved narcotic pain relievers (55 percent) and benzodiazepines (47 percent). Of all the carisoprodol visits classified as misuse or abuse, one third (35 percent) of the visits required hospitalization.

Other topics

Other OAS publications and services

This Short Report The DAWN Report: ED Visits Involving the Muscle Relaxant Carisoprodol is based on the Drug Abuse Warning Network (DAWN) conducted by SAMHSA's Office of Applied Studies (OAS) in the Substance Abuse and Mental Health Services Administration (SAMHSA).  SAMHSA's National Survey on Drug Use and Health is the primary source of information on the prevalence, patterns, and consequences of drug and alcohol use and abuse in the general U.S. civilian non institutionalized population, age 12 and older.

This is the page footer.

This page has been accessed 531 times since 10/27/11.

This page was last updated on October 27, 2011.

SAMHSA, an agency in the Department of Health and Human Services, is the Federal Government's lead agency for improving the quality and availability of substance abuse prevention, addiction treatment, and mental health services in the United States.

This is a line.

   Site Map | Contact Us | Accessibility | Privacy Policy | Freedom of Information Act
 Disclaimer | Department of Health and Human Services | SAMHSA | White House | USA.gov

* PDF formatted files require that Adobe Acrobat Reader® program is installed on your computer. Click here to download this FREE software now from Adobe.